Testing version — LOERadar is in active testing. Features and data may change.
PAXIL (PAROXETINE HYDROCHLORIDE) | LOERadar
PAXIL
NDA
PAROXETINE HYDROCHLORIDE | N020885 | APOTEX INC
4 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
#001 — EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
CAPSULE;ORAL | Approved: Oct 9, 1998
No patent or exclusivity listings for this strength.
#002 — EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Oct 9, 1998
#003 — EQ 30MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Oct 9, 1998
#004 — EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**